DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Novartis acquires US pharma research firm Selexys Pharmaceuticals
Swiss-based pharmaceuticals giant Novartis said Monday it was acquiring Selexys Pharmaceuticals Corp., a US research lab in blood and inflammatory disorders, in a deal costing up to $665 million (627 million euros).
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
In a statement, Novartis said it exercised rights to buy the company after seeing results from a large trial into a drug to treat pain for people with the disease.


Related Content
-
videos & visualsHow to Talk to Your Child About Hydroxyureahttps://www.youtube.com/watch?v=_apTt2j0...
-
Community CenterToday’s Faces of Sickle Cell Disease: Deidra Flowers-WilliamsAt six months of age, Deidra Flowers-Wil...
-
news & eventsGene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
education & researchHydroxyurea Therapy Prevents High Risk Trans-Cranial Doppler Development in Children with Sickle Cell DisordersAnnual evaluation by Trans-Cranial Doppl...
-
education & researchPredictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role ...Despite its rarity in the United States,...
-
news & eventsMARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-m...Hematopoietic stem cell transplant for s...
-
videos & visualsTeen is one of the first ever to get his genes editedhttps://www.youtube.com/watch?v=0xv0CBuj...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.